References

1.
Siegel R, Ward E, Brawley O, et al. Cancer statistics, 2011: The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011;61:212–236. [PubMed: 21685461]
2.
Ries LAG, Young JL, Keel GE, et al. Patient and Tumor Characteristics. Bethesda, MD: National Cancer Institute; 2007. SEER Survival Monograph: Cancer Survival Among Adults: U.S. SEER Program, 1988–2001.
3.
National Cancer Institute Cancer. Trends Progress Report - 2009/2010 Update. Bethesda, MD: National Institutes of Health; 2010.
4.
Cooperberg MR, Lubeck DP, Mehta SS, et al. Time trends in clinical risk stratification for prostate cancer: implications for outcomes (data from CaPSURE) J Urol. 2003;170:S21–S25. [PubMed: 14610406]
5.
Cooperberg MR, Grossfeld GD, Lubeck DP, et al. National practice patterns and time trends in androgen ablation for localized prostate cancer. J Natl Cancer Inst. 2003;95:981–989. [PMC free article: PMC2994265] [PubMed: 12837834]
6.
Agency for Healthcare Research and Quality. Methods Reference Guide for Effectiveness and Comparative Effectiveness Reviews, Version 1.0. 2010. Ref Type: Generic.
7.
Martin RM, Gunnell D, Hamdy F, et al. Continuing controversy over monitoring men with localized prostate cancer: a systematic review of programs in the prostate specific antigen era. [Review] [45 refs] Journal of Urology. 2006;176:439–449. [PMC free article: PMC2875171] [PubMed: 16813862]
8.
Ip S, Dvorak T, Yu WW, et al. Comparative evaluation of radiation treatments for clinically localized prostate cancer: an update. [Ref Type: Generic]. Available at: http://www​.cms.gov/mcd/viewtechassess​.asp?where​=index&tid=69. August 13, 2010. [PubMed: 21646550]
9.
Wilt TJ, MacDonald R, Rutks I, et al. Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer. Ann Intern Med. 2008;148:435–448. [PubMed: 18252677]
10.
Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151:264–9. W64. [PubMed: 19622511]
11.
Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000;283:2008–2012. [PubMed: 10789670]
12.
Shea BJ, Grimshaw JM, Wells GA, et al. Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. BMC Med Res Methodol. 2007;7:10. [PMC free article: PMC1810543] [PubMed: 17302989]
13.
Shea BJ, Hamel C, Wells GA, et al. AMSTAR is a reliable and valid measurement tool to assess the methodological quality of systematic reviews. J Clin Epidemiol. 2009;62:1013–1020. [PubMed: 19230606]
14.
Altman DG, Bland JM. Presentation of numerical data. BMJ. 1996;312:572. [PMC free article: PMC2350327] [PubMed: 8595293]
15.
Owens DK, Lohr KN, Atkins D, et al. AHRQ series paper 5: grading the strength of a body of evidence when comparing medical interventions—agency for healthcare research and quality and the effective health-care program. J Clin Epidemiol. 2010;63:513–523. [PubMed: 19595577]
16.
Mebane C, Gibbs T, Horm J. Current status of prostate cancer in North American black males. J Natl Med Assoc. 1990;82:782–788. [PMC free article: PMC2626941] [PubMed: 2258952]
17.
Hankey BF, Feuer EJ, Clegg LX, et al. Cancer surveillance series: interpreting trends in prostate cancer—part I: Evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates. J Natl Cancer Inst. 1999;91:1017–1024. [PubMed: 10379964]
18.
Chu KC, Tarone RE, Freeman HP. Trends in prostate cancer mortality among black men and white men in the United States. Cancer. 2003;97:1507–1516. [PubMed: 12627516]
19.
Brawley OW. Prostate carcinoma incidence and patient mortality: the effects of screening and early detection. Cancer. 1997;80:1857–1863. [PubMed: 9351560]
20.
Merrill RM, Brawley OW. Prostate cancer incidence and mortality rates among white and black men. Epidemiology. 1997;8:126–131. [PubMed: 9229202]
21.
Farkas A, Schneider D, Perrotti M, et al. National trends in the epidemiology of prostate cancer, 1973 to 1994: evidence for the effectiveness of prostate-specific antigen screening. Urology. 1998;52:444–448. [PubMed: 9730458]
22.
Perrotti M, Rabbani F, Farkas A, et al. Trends in poorly differentiated prostate cancer 1973 to 1994: observations from the Surveillance, Epidemiology and End Results database. J Urol. 1998;160:811–815. [PubMed: 9720554]
23.
Dennis LK, Resnick MI. Analysis of recent trends in prostate cancer incidence and mortality. Prostate. 2000;42:247–252. [PubMed: 10679753]
24.
Merrill RM, Lyon JL. Explaining the difference in prostate cancer mortality rates between white and black men in the United States. Urology. 2000;55:730–735. [PubMed: 10792091]
25.
Clegg LX, Feuer EJ, Midthune DN, et al. Impact of reporting delay and reporting error on cancer incidence rates and trends. J Natl Cancer Inst. 2002;94:1537–1545. [PubMed: 12381706]
26.
Stephenson RA. Prostate cancer trends in the era of prostate-specific antigen. An update of incidence, mortality, and clinical factors from the SEER database. Urol Clin North Am. 2002;29:173–181. [PubMed: 12109343]
27.
Escobedo LG, Rivas SD, Holmes MD. Prostate cancer mortality in Connecticut, Iowa and New Mexico African American men. Cancer Detect Prev. 2004;28:375–380. [PubMed: 15542264]
28.
McDavid K, Lee J, Fulton JP, et al. Prostate cancer incidence and mortality rates and trends in the United States and Canada. Public Health Rep. 2004;119:174–186. [PMC free article: PMC1497609] [PubMed: 15192905]
29.
Hayat MJ, Howlader N, Reichman ME, et al. Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program. Oncologist. 2007;12:20–37. [PubMed: 17227898]
30.
Jani AB, Johnstone PA, Liauw SL, et al. Age and grade trends in prostate cancer (1974–2003): a Surveillance, Epidemiology, and End Results Registry analysis. Am J Clin Oncol. 2008;31:375–378. [PubMed: 18845997]
31.
Clegg LX, Li FP, Hankey BF, Chu K, Edwards BK. Cancer survival among US whites and minorities: a SEER (Surveillance, Epidemiology, and End Results) Program population-based study. Arch Intern Med. 2002;162:1985–1993. [PubMed: 12230422]
32.
Merrill RM, Morris MK. Prevalence-corrected prostate cancer incidence rates and trends. Am J Epidemiol. 2002;155:148–152. [PubMed: 11790678]
33.
Collin SM, Martin RM, Metcalfe C, et al. Prostate-cancer mortality in the USA and UK in 1975–2004: an ecological study. Lancet Oncol. 2008;9:445–452. [PMC free article: PMC2760747] [PubMed: 18424233]
34.
Sarma AV, Schottenfeld D. Prostate cancer incidence, mortality, and survival trends in the United States: 1981–2001. Semin Urol Oncol. 2002;20:3–9. [PubMed: 11828352]
35.
Lu-Yao GL, Greenberg ER. Changes in prostate cancer incidence and treatment in USA. Lancet. 1994;343:251–254. [PubMed: 7905093]
36.
Harlan L, Brawley O, Pommerenke F, et al. Geographic, age, and racial variation in the treatment of local/regional carcinoma of the prostate. J Clin Oncol. 1995;13:93–100. [PubMed: 7799048]
37.
Jani AB, Master VA, Rossi PJ, et al. Grade migration in prostate cancer: an analysis using the Surveillance, Epidemiology, and End Results registry. Prostate Cancer Prostatic Dis. 2007;10:347–351. [PubMed: 17505529]
38.
Welch HG, Albertsen PC. Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986–2005. J Natl Cancer Inst. 2009;101:1325–1329. [PMC free article: PMC2758309] [PubMed: 19720969]
39.
Devesa SS, Blot WJ, Stone BJ, et al. Recent cancer trends in the United States. J Natl Cancer Inst. 1995;87:175–182. [PubMed: 7707404]
40.
Merrill RM, Stephenson RA. Trends in mortality rates in patients with prostate cancer during the era of prostate specific antigen screening. J Urol. 2000;163:503–510. [PubMed: 10647666]
41.
Miller DC, Gruber SB, Hollenbeck BK, et al. Incidence of initial local therapy among men with lower-risk prostate cancer in the United States. J Natl Cancer Inst. 2006;98:1134–1141. [PubMed: 16912266]
42.
Shao YH, Demissie K, Shih W, et al. Contemporary risk profile of prostate cancer in the United States. J Natl Cancer Inst. 2009;101:1280–1283. [PMC free article: PMC2744729] [PubMed: 19713548]
43.
Merrill RM, Potosky AL, Feuer EJ. Changing trends in U.S. prostate cancer incidence rates. J Natl Cancer Inst. 1996;88:1683–1685. [PubMed: 8931614]
44.
Stewart SL, King JB, Thompson TD, et al. Cancer mortality surveillance--United States, 1990–2000. MMWR Surveill Summ. 2004;53:1–108. [PubMed: 15179359]
45.
Zhu K, Devesa SS, Wu H, et al. Cancer incidence in the U.S. military population: comparison with rates from the SEER program. Cancer Epidemiol Biomarkers Prev. 2009;18:1740–1745. [PMC free article: PMC2780333] [PubMed: 19505907]
46.
Polednak AP. Black-white differences in tumor grade (aggressiveness) at diagnosis of prostate cancer, 1992–1998. Ethn Dis. 2002;12:536–540. [PubMed: 12477140]
47.
Underwood W III, Jackson J, Wei JT, et al. Racial treatment trends in localized/regional prostate carcinoma: 1992–1999. Cancer. 2005;103:538–545. [PubMed: 15612083]
48.
Underwood W, De MS, Ubel P, et al. Racial/ethnic disparities in the treatment of localized/regional prostate cancer. J Urol. 2004;171:1504–1507. [PubMed: 15017208]
49.
Demers RY, Swanson GM, Weiss LK, et al. Increasing incidence of cancer of the prostate. The experience of black and white men in the Detroit metropolitan area. Arch Intern Med. 1994;154:1211–1216. [PubMed: 8203988]
50.
Severson RK, Montie JE, Porter AT, et al. Recent trends in incidence and treatment of prostate cancer among elderly men. J Natl Cancer Inst. 1995;87:532–534. [PubMed: 7707440]
51.
Demers RY, Tiwari A, Wei J, et al. Trends in the utilization of androgen-deprivation therapy for patients with prostate carcinoma suggest an effect on mortality. Cancer. 2001;92:2309–2317. [PubMed: 11745285]
52.
Schwartz KL, Grignon DJ, Sakr WA, et al. Prostate cancer histologic trends in the metropolitan Detroit area, 1982 to 1996. Urology. 1999;53:769–774. [PubMed: 10197854]
53.
Gilliland FD, Hunt WC, Key CR. Ethnic variation in prostate cancer survival in New Mexico. Cancer Epidemiol Biomarkers Prev. 1996;5:247–251. [PubMed: 8722215]
54.
Gilliland FD, Gleason DF, Hunt WC, et al. Trends in Gleason score for prostate cancer diagnosed between 1983 and 1993. J Urol. 2001;165:846–850. [PubMed: 11176484]
55.
Newcomer LM, Stanford JL, Blumenstein BA, et al. Temporal trends in rates of prostate cancer: declining incidence of advanced stage disease, 1974 to 1994. J Urol. 1997;158:1427–1430. [PubMed: 9302136]
56.
Stephenson RA, Smart CR, Mineau GP, et al. The fall in incidence of prostate carcinoma. On the down side of a prostate specific antigen induced peak in incidence— data from the Utah Cancer Registry. Cancer. 1996;77:1342–1348. [PubMed: 8608513]
57.
Potosky AL, Miller BA, Albertsen PC, et al. The role of increasing detection in the rising incidence of prostate cancer. JAMA. 1995;273:548–552. [PubMed: 7530782]
58.
Klabunde CN, Potosky AL, Harlan LC, et al. Trends and black/white differences in treatment for nonmetastatic prostate cancer. Med Care. 1998;36:1337–1348. [PubMed: 9749657]
59.
Sheikh K, Bullock C. Rise and fall of radical prostatectomy rates from 1989 to 1996. Urology. 2002;59:378–382. [PubMed: 11880074]
60.
Godley PA, Schenck AP, Amamoo MA, et al. Racial differences in mortality among Medicare recipients after treatment for localized prostate cancer. J Natl Cancer Inst. 2003;95:1702–1710. [PubMed: 14625261]
61.
Zeliadt SB, Potosky AL, Etzioni R, et al. Racial disparity in primary and adjuvant treatment for nonmetastatic prostate cancer: SEER-Medicare trends 1991 to 1999. Urology. 2004;64:1171–1176. [PubMed: 15596192]
62.
Carpenter WR, Howard DL, Taylor YJ, et al. Racial differences in PSA screening interval and stage at diagnosis. Cancer Causes Control. 2010;21:1071–1080. [PMC free article: PMC2883656] [PubMed: 20333462]
63.
Mullins CD, Onukwugha E, Bikov K, et al. Health disparities in staging of SEER-medicare prostate cancer patients in the United States. Urology. 2010;76:566–572. [PMC free article: PMC3736596] [PubMed: 20163844]
64.
Kindrick AV, Grossfeld GD, Stier DM, et al. Use of imaging tests for staging newly diagnosed prostate cancer: trends from the CaPSURE database. J Urol. 1998;160:2102–2106. [PubMed: 9817332]
65.
Cooperberg MR, Lubeck DP, Grossfeld GD, et al. Contemporary trends in imaging test utilization for prostate cancer staging: data from the cancer of the prostate strategic urologic research endeavor. J Urol. 2002;168:491–495. [PubMed: 12131295]
66.
Harlan SR, Cooperberg MR, Elkin EP, et al. Time trends and characteristics of men choosing watchful waiting for initial treatment of localized prostate cancer: results from CaPSURE. J Urol. 2003;170:1804–1807. [PubMed: 14532780]
67.
Cooperberg MR, Lubeck DP, Meng MV, et al. The changing face of low-risk prostate cancer: trends in clinical presentation and primary management. J Clin Oncol. 2004;22:2141–2149. [PMC free article: PMC2997214] [PubMed: 15169800]
68.
Cooperberg MR, Broering JM, Kantoff PW, et al. Contemporary trends in low risk prostate cancer: risk assessment and treatment. J Urol. 2007;178:S14–S19. [PMC free article: PMC2987559] [PubMed: 17644125]
69.
Cooperberg MR, Broering JM, Carroll PR. Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol. 2010;28:1117–1123. [PMC free article: PMC2834465] [PubMed: 20124165]
70.
Shah JB, McKiernan JM, Elkin EP, et al. Prostate biopsy patterns in the CaPSURE database: evolution with time and impact on outcome after prostatectomy. J Urol. 2008;179:136–140. [PubMed: 17997437]
71.
Greene KL, Cowan JE, Cooperberg MR, et al. Who is the average patient presenting with prostate cancer? Urology. 2005;66:76–82. [PubMed: 16194711]
72.
Mettlin CJ, Murphy G. The National Cancer Data Base report on prostate cancer. Cancer. 1994;74:1640–1648. [PubMed: 8062197]
73.
Mettlin CJ, Murphy GP, Ho R, et al. The National Cancer Data Base report on longitudinal observations on prostate cancer. Cancer. 1996;77:2162–2166. [PubMed: 8640686]
74.
Mettlin CJ, Murphy GP, McGinnis LS, et al. The National Cancer Data Base report on prostate cancer. American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer. 1995;76:1104–1112. [PubMed: 8625214]
75.
Mettlin CJ, Murphy GP, Rosenthal DS, et al. The National Cancer Data Base report on prostate carcinoma after the peak in incidence rates in the U.S. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer. 1998;83:1679–1684. [PubMed: 9781963]
76.
Danley KL, Richardson JL, Bernstein L, et al. Prostate cancer: trends in mortality and stage-specific incidence rates by racial/ethnic group in Los Angeles County, California (United States) Cancer Causes Control. 1995;6:492–498. [PubMed: 8580296]
77.
Hamilton AS, Albertsen PC, Johnson TK, et al. Trends in the treatment of localized prostate cancer using supplemented cancer registry data. BJU Int. 2011;107:576–584. [PubMed: 20735387]
78.
Smart CR. The results of prostate carcinoma screening in the U.S. as reflected in the surveillance, epidemiology, and end results program. Cancer. 1997;80:1835–1844. [PubMed: 9351557]
79.
Merrill RM, Feuer EJ, Warren JL, et al. Role of transurethral resection of the prostate in population-based prostate cancer incidence rates. Am J Epidemiol. 1999;150:848–860. [PubMed: 10522656]
80.
Hsing AW, Tsao L, Devesa SS. International trends and patterns of prostate cancer incidence and mortality. Int J Cancer. 2000;85:60–67. [PubMed: 10585584]
81.
Mariotto AB, Wesley MN, Cronin KA, et al. Estimates of long-term survival for newly diagnosed cancer patients: a projection approach. Cancer. 2006;106:2039–2050. [PubMed: 16572414]
82.
Abdollah F, Sun M, Thuret R, et al. A competing-risks analysis of survival after alternative treatment modalities for prostate cancer patients: 1988–2006. Eur Urol. 2011;59:88–95. [PubMed: 20965646]
83.
Paltoo DN, Chu KC. Patterns in cancer incidence among American Indians/Alaska Natives, United States, 1992–1999. Public Health Rep. 2004;119:443–451. [PMC free article: PMC1497649] [PubMed: 15219802]
84.
Kohler BA, Ward E, McCarthy BJ, et al. Annual report to the nation on the status of cancer, 1975–2007, featuring tumors of the brain and other nervous system. J Natl Cancer Inst. 2011;103:714–736. [PMC free article: PMC3086878] [PubMed: 21454908]
85.
Schwartz KL, Severson RK, Gurney JG, et al. Trends in the stage specific incidence of prostate carcinoma in the Detroit metropolitan area, 1973–1994. Cancer. 1996;78:1260–1266. [PubMed: 8826949]
86.
Barnholtz-Sloan JS, Severson RK, Vaishampayan U, et al. Survival analysis of distant prostate cancer by decade (1973–1997) in the Detroit Metropolitan Surveillance, Epidemiology and End Results (SEER) Program registry: has outcome improved? (United States) Cancer Causes Control. 2003;14:681–685. [PubMed: 14575366]
87.
Warren JL, Yabroff KR, Meekins A, et al. Evaluation of trends in the cost of initial cancer treatment. J Natl Cancer Inst. 2008;100:888–897. [PMC free article: PMC3298963] [PubMed: 18544740]
88.
Gross CP, Smith BD, Wolf E, et al. Racial disparities in cancer therapy: did the gap narrow between 1992 and 2002? Cancer. 2008;112:900–908. [PMC free article: PMC3535295] [PubMed: 18181101]
89.
Welch HG, Fisher ES, Gottlieb DJ, et al. Detection of prostate cancer via biopsy in the Medicare-SEER population during the PSA era. J Natl Cancer Inst. 2007;99:1395–1400. [PubMed: 17848671]
90.
Cooperberg MR, Cowan J, Broering JM, et al. High-risk prostate cancer in the United States, 1990–2007. World J Urol. 2008;26:211–218. [PMC free article: PMC2948572] [PubMed: 18369637]
91.
Mettlin CJ, Murphy GP, McDonald CJ, et al. The National Cancer Data base Report on increased use of brachytherapy for the treatment of patients with prostate carcinoma in the U.S. Cancer. 1999;86:1877–1882. [PubMed: 10547563]
92.
White A, Coker AL, Du XL, et al. Racial/ethnic disparities in survival among men diagnosed with prostate cancer in Texas. Cancer. 2011;117:1080–1088. [PMC free article: PMC3100436] [PubMed: 21351084]
93.
Frey CM, McMillen MM, Cowan CD, et al. Representativeness of the surveillance, epidemiology, and end results program data: recent trends in cancer mortality rates. J Natl Cancer Inst. 1992;84:872–877. [PubMed: 1593655]
94.
Merrill RM, Dearden KA. How representative are the surveillance, epidemiology, and end results (SEER) program cancer data of the United States? Cancer Causes Control. 2004;15:1027–1034. [PubMed: 15801487]
95.
Warren JL, Klabunde CN, Schrag D, et al. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care. 2002;40:IV-18. [PubMed: 12187163]
96.
Etzioni R, Penson DF, Legler JM, et al. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst. 2002;94:981–990. [PubMed: 12096083]
97.
Albertsen PC, Hanley JA, Barrows GH, et al. Prostate cancer and the Will Rogers phenomenon. J Natl Cancer Inst. 2005;97:1248–1253. [PubMed: 16145045]
98.
Feinstein AR, Sosin DM, Wells CK. The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. N Engl J Med. 1985;312:1604–1608. [PubMed: 4000199]
99.
Gofrit ON, Zorn KC, Steinberg GD, et al. The Will Rogers phenomenon in urological oncology. J Urol. 2008;179:28–33. [PubMed: 17997434]
100.
Feuer EJ, Merrill RM, Hankey BF. Cancer surveillance series: interpreting trends in prostate cancer--part II: Cause of death misclassification and the recent rise and fall in prostate cancer mortality. J Natl Cancer Inst. 1999;91:1025–1032. [PubMed: 10379965]
101.
Tsodikov A, Szabo A, Wegelin J. A population model of prostate cancer incidence. Stat Med. 2006;25:2846–2866. [PubMed: 16397859]
102.
Etzioni R, Tsodikov A, Mariotto A, et al. Quantifying the role of PSA screening in the US prostate cancer mortality decline. Cancer Causes Control. 2008;19:175–181. [PMC free article: PMC3064270] [PubMed: 18027095]
103.
Telesca D, Etzioni R, Gulati R. Estimating lead time and overdiagnosis associated with PSA screening from prostate cancer incidence trends. Biometrics. 2008;64:10–19. [PubMed: 17501937]
104.
Draisma G, Postma R, Schroder FH, et al. Gleason score, age and screening: modeling dedifferentiation in prostate cancer. Int J Cancer. 2006;119:2366–2371. [PubMed: 16858675]
105.
Draisma G, Etzioni R, Tsodikov A, et al. Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J Natl Cancer Inst. 2009;101:374–383. [PMC free article: PMC2720697] [PubMed: 19276453]
106.
Patel MI, DeConcini DT, Lopez-Corona E, et al. An analysis of men with clinically localized prostate cancer who deferred definitive therapy. J Urol. 2004;171:1520–1524. [PubMed: 15017211]
107.
Al OM, Ross P, Fahmy N, et al. Role of repeated biopsy of the prostate in predicting disease progression in patients with prostate cancer on active surveillance. Cancer. 2008;113:286–292. [PubMed: 18484590]
108.
Ercole B, Marietti SR, Fine J, et al. Outcomes following active surveillance of men with localized prostate cancer diagnosed in the prostate specific antigen era. J Urol. 2008;180:1336–1339. [PubMed: 18707696]
109.
Eggener SE, Mueller A, Berglund RK, et al. A multi-institutional evaluation of active surveillance for low risk prostate cancer. J Urol. 2009;181:1635–1641. [PMC free article: PMC4237227] [PubMed: 19233410]
110.
Soloway MS, Soloway CT, Williams S, et al. Active surveillance; a reasonable management alternative for patients with prostate cancer: the Miami experience. BJU Int. 2008;101:165–169. [PubMed: 17850361]
111.
Dall’era MA, Konety BR, Cowan JE, et al. Active surveillance for the management of prostate cancer in a contemporary cohort. Cancer. 2008;112:2664–2670. [PubMed: 18433013]
112.
Hardie C, Parker C, Norman A, et al. Early outcomes of active surveillance for localized prostate cancer. BJU Int. 2005;95:956–960. [PubMed: 15839912]
113.
Ross AE, Loeb S, Landis P, et al. Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program. J Clin Oncol. 2010;28:2810–2816. [PubMed: 20439642]
114.
Choo R, Deboer G, Klotz L, et al. PSA doubling time of prostate carcinoma managed with watchful observation alone. Int J Radiat Oncol Biol Phys. 2001;50:615–620. [PubMed: 11395227]
115.
Adamy A, Yee DS, Matsushita K, et al. Role of prostate specific antigen and immediate confirmatory biopsy in predicting progression during active surveillance for low risk prostate cancer. J Urol. 2011;185:477–482. [PMC free article: PMC3417207] [PubMed: 21167529]
116.
Metcalfe C, Tilling K, Davis M, et al. Current strategies for monitoring men with localised prostate cancer lack a strong evidence base: observational longitudinal study. Br J Cancer. 2009;101:390–394. [PMC free article: PMC2720224] [PubMed: 19603015]
117.
San FI, Werner L, Regan MM, et al. Risk stratification and validation of prostate specific antigen density as independent predictor of progression in men with low risk prostate cancer during active surveillance. J Urol. 2011;185:471–476. [PubMed: 21167525]
118.
Kakehi Y, Kamoto T, Shiraishi T, et al. Prospective evaluation of selection criteria for active surveillance in Japanese patients with stage T1cN0M0 prostate cancer. Jpn J Clin Oncol. 2008;38:122–128. [PubMed: 18272471]
119.
Miocinovic R, Jones JS, Pujara AC, et al. Acceptance and durability of surveillance as a management choice in men with screen-detected, low-risk prostate cancer: improved outcomes with stringent enrollment criteria. Urology. 2011;77:980–984. [PubMed: 21256549]
120.
van den Bergh RC, Vasarainen H, van der Poel HG, et al. Short-term outcomes of the prospective multicentre 'Prostate Cancer Research International: Active Surveillance' study. BJU Int. 2010;105:956–962. [PubMed: 19817747]
121.
Newcomb LF, Brooks JD, Carroll PR, et al. Canary Prostate Active Surveillance Study: design of a multi-institutional active surveillance cohort and biorepository. Urology. 2010;75:407–413. [PMC free article: PMC3827723] [PubMed: 19758683]
122.
Gorin MA, Soloway CT, Eldefrawy A, et al. Factors that influence patient enrollment in active surveillance for low-risk prostate cancer. Urology. 2011;77:588–591. [PubMed: 21215429]
123.
Soloway MS, Soloway CT, Eldefrawy A, et al. Careful selection and close monitoring of low-risk prostate cancer patients on active surveillance minimizes the need for treatment. Eur Urol. 2010;58:831–835. [PubMed: 20800964]
124.
Venkitaraman R, Norman A, Woode- Amissah R, et al. Prostate-specific antigen velocity in untreated, localized prostate cancer. BJU Int. 2008;101:161–164. [PubMed: 17850368]
125.
Klotz L, Zhang L, Lam A, et al. A Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol. 2010;28:126–131. [PubMed: 19917860]
126.
Fryback DG, Albertsen PC, Storer BE. Prostatectomy and survival among men with clinically localized prostate cancer. JAMA. 1996;276:1723–1724. [PubMed: 8940318]
127.
Neulander EZ, Duncan RC, Tiguert R, et al. Deferred treatment of localized prostate cancer in the elderly: the impact of the age and stage at the time of diagnosis on the treatment decision. BJU Int. 2000;85:699–704. [PubMed: 10759669]
128.
Venkitaraman R, Thomas K, Grace P, et al. Baseline urinary phytoestrogen levels and the natural history of untreated, localised prostate cancer in a British population. Int J Biol Markers. 2008;23:192–197. [PubMed: 18949747]
129.
Krakowsky Y, Loblaw A, Klotz L. Prostate cancer death of men treated with initial active surveillance: clinical and biochemical characteristics. J Urol. 2010;184:131–135. [PubMed: 20478589]
130.
Loblaw A, Zhang L, Lam A, et al. Comparing prostate specific antigen triggers for intervention in men with stable prostate cancer on active surveillance. J Urol. 2010;184:1942–1946. [PubMed: 20846681]
131.
Cooperberg MR, Cowan JE, Hilton JF, et al. Outcomes of active surveillance for men with intermediate-risk prostate cancer. J Clin Oncol. 2011;29:228–234. [PMC free article: PMC3058278] [PubMed: 21115873]
132.
Whitson JM, Porten SP, Hilton JF, et al. The relationship between prostate specific antigen change and biopsy progression in patients on active surveillance for prostate cancer. J Urol. 2011;185:1656–1660. [PubMed: 21419438]
133.
Chan JM, Weinberg V, Magbanua MJ, et al. Nutritional supplements, COX-2 and IGF-1 expression in men on active surveillance for prostate cancer. Cancer Causes & Control. 2011;22:141–150. [PMC free article: PMC3002170] [PubMed: 21103921]
134.
Giles SL, Morgan VA, Riches SF, et al. Apparent diffusion coefficient as a predictive biomarker of prostate cancer progression: value of fast and slow diffusion components. AJR. 2011.:586–591. American. [PubMed: 21343500]
135.
Porten SP, Whitson JM, Cowan JE, et al. Changes in prostate cancer grade on serial biopsy in men undergoing active surveillance. Journal of Clinical Oncology. 2011;29:2795–2800. [PubMed: 21632511]
136.
Ng MK, Van AN, Thomas K, et al. Prostate-specific antigen (PSA) kinetics in untreated, localized prostate cancer: PSA velocity vs PSA doubling time. BJU Int. 2009;103:872–876. [PubMed: 18990146]
137.
Carter HB, Kettermann A, Warlick C, et al. Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience. J Urol. 2007;178:2359–2364. [PubMed: 17936806]
138.
Jones GW. Prospective, conservative management of localized prostate cancer. Cancer. 1992;70:307–310. [PubMed: 1600492]
139.
Johansson JE. Expectant management of early stage prostatic cancer: Swedish experience. J Urol. 1994;152:1753–1756. [PubMed: 7933233]
140.
Adolfsson J, Tribukait B, Levitt S. The 20- Yr outcome in patients with well- or moderately differentiated clinically localized prostate cancer diagnosed in the pre-PSA era: the prognostic value of tumour ploidy and comorbidity. Eur Urol. 2007;52:1028–1035. [PubMed: 17467883]
141.
Handley R, Carr TW, Travis D, et al. Deferred treatment for prostate cancer. Br J Urol. 1988;62:249–253. [PubMed: 3191340]
142.
Rana A, Chisholm GD, Christodoulou S, et al. Audit and its impact in the management of early prostatic cancer. Br J Urol. 1993;71:721–727. [PubMed: 8343901]
143.
Chen WM, Yang CR, Ou YC, et al. Clinical outcome of patients with stage T1a prostate cancer. J Chin Med Assoc. 2003;66:236–240. [PubMed: 12854876]
144.
Holmberg L, Bill-Axelson A, Helgesen F, et al. A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med. 2002;347:781–789. [PubMed: 12226148]
145.
Bangma CH, HOP WCJ, Schroder FH. Serial prostate specific antigen measurements and progression in untreated confined (stages T0 to 3NxM0, grades 1 to 3) carcinoma of the prostate. J Urol. 1995;154:1403–1406. [PubMed: 7544841]
146.
Wilt TJ, Brawer MK, Barry MJ, et al. The Prostate cancer Intervention Versus Observation Trial:VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer. Contemp Clin Trials. 2009;30:81–87. [PubMed: 18783735]
147.
Stratton MS, Reid ME, Schwartzberg G, et al. Selenium and inhibition of disease progression in men diagnosed with prostate carcinoma: study design and baseline characteristics of the 'Watchful Waiting' Study. Anticancer Drugs. 2003;14:595–600. [PubMed: 14501381]
148.
McIntyre IG, Clarke RB, Anderson E, et al. Molecular prediction of progression in patients with conservatively managed prostate cancer. Urology. 2001;58:762–766. [PubMed: 11711356]
149.
Anai S, Nakamura K, Chang MN, et al. The feasibility of expectant management with inner-city men with newly diagnosed localized prostate cancer. J Health Care Poor Underserved. 2008;19:164–170. [PubMed: 18263992]
150.
Roemeling S, Roobol MJ, de Vries SH, et al. Active surveillance for prostate cancers detected in three subsequent rounds of a screening trial: characteristics, PSA doubling times, and outcome. Eur Urol. 2007;51:1244–1250. [PubMed: 17161520]
151.
van den Bergh RC, Roemeling S, Roobol MJ, et al. Outcomes of men with screen-detected prostate cancer eligible for active surveillance who were managed expectantly. Eur Urol. 2009;55:1–8. [PubMed: 18805628]
152.
Tilling K, Garmo H, Metcalfe C, et al. Development of a new method for monitoring prostate-specific antigen changes in men with localised prostate cancer: a comparison of observational cohorts. Eur Urol. 2010;57:446–452. [PMC free article: PMC2910432] [PubMed: 19303695]
153.
Kakehi Y, Kamoto T, Ogawa O, et al. Clinical significance of nonpalpable prostate cancer with favorable biopsy features in Japanese men. Eur Urol. 2000;37:552–558. [PubMed: 10765093]
154.
Arai Y, Egawa S, Kuwao S, et al. The role of volume-weighted mean nuclear volume in predicting tumour biology and clinical behaviour in patients with prostate cancer undergoing watchful waiting. BJU Int. 2001;88:909–914. [PubMed: 11851612]
155.
Mohler JL, Williams BT, Freeman JA. Expectant management as an option for men with stage T1c prostate cancer: a preliminary study. World J Urol. 1997;15:364–368. [PubMed: 9436286]
156.
Finelli A, Trottier G, Lawrentschuk N, et al. Impact of 5alpha-reductase inhibitors on men followed by active surveillance for prostate cancer. Eur Urol. 2011;59:509–514. [PubMed: 21211899]
157.
McLaren DB, McKenzie M, Duncan G, et al. Watchful waiting or watchful progression?: Prostate specific antigen doubling times and clinical behavior in patients with early untreated prostate carcinoma. Cancer. 1998;82:342–348. [PubMed: 9445192]
158.
Lee EK, Baack J, Penn H, et al. Active surveillance for prostate cancer in a veteran population. Can J Urol. 2010;17:5429–5435. [PubMed: 21172105]
159.
Snyder CF, Frick KD, Blackford AL, et al. How does initial treatment choice affect short-term and long-term costs for clinically localized prostate cancer? Cancer. 2010;116:5391–5399. [PubMed: 20734396]
160.
Dall’era MA, Hosang N, Konety B, et al. Sociodemographic predictors of prostate cancer risk category at diagnosis: unique patterns of significant and insignificant disease. J Urol. 2009;181:1622–1627. [PubMed: 19230923]
161.
Barocas DA, Cowan JE, Smith JA Jr, et al. What percentage of patients with newly diagnosed carcinoma of the prostate are candidates for surveillance? An analysis of the CaPSURE database. J Urol. 2008;180:1330–1334. [PubMed: 18707731]
162.
Konety BR, Cowan JE, Carroll PR. Patterns of primary and secondary therapy for prostate cancer in elderly men: analysis of data from CaPSURE. J Urol. 2008;179:1797–1803. [PubMed: 18343440]
163.
Sadetsky N, Elkin EP, Latini DM, et al. Prostate cancer outcomes among older men: insurance status comparisons results from CaPSURE database. Prostate Cancer Prostatic Dis. 2008;11:280–287. [PubMed: 17893700]
164.
Latini DM, Hart SL, Knight SJ, et al. The relationship between anxiety and time to treatment for patients with prostate cancer on surveillance. J Urol. 2007;178:826–831. [PubMed: 17632144]
165.
Marr PL, Elkin EP, Arredondo SA, et al. Comorbidity and primary treatment for localized prostate cancer: data from CaPSURE. J Urol. 2006;175:1326–1331. [PubMed: 16515991]
166.
Shavers VL, Brown ML, Potosky AL, et al. Race/ethnicity and the receipt of watchful waiting for the initial management of prostate cancer. J Gen Intern Med. 2004;19:146–155. [PMC free article: PMC1492143] [PubMed: 15009794]
167.
Meng MV, Elkin EP, Harlan SR, et al. Predictors of treatment after initial surveillance in men with prostate cancer: results from CaPSURE. J Urol. 2003;170:2279–2283. [PubMed: 14634396]
168.
Koppie TM, Grossfeld GD, Miller D, et al. Patterns of treatment of patients with prostate cancer initially managed with surveillance: results from The CaPSURE database. Cancer of the Prostate Strategic Urological Research Endeavor. J Urol. 2000;164:81–88. [PubMed: 10840429]
169.
Moses KA, Paciorek AT, Penson DF, et al. Impact of ethnicity on primary treatment choice and mortality in men with prostate cancer: data from CaPSURE. J Clin Oncol. 2010;28:1069–1074. [PMC free article: PMC2834431] [PubMed: 20100957]
170.
Latini DM, Elkin EP, Cooperberg MR, et al. Differences in clinical characteristics and disease-free survival for Latino, African American, and non-Latino white men with localized prostate cancer: data from CaPSURE. Cancer. 2006;106:789–795. [PubMed: 16400651]
171.
Wolters T, Roobol MJ, Steyerberg EW, et al. The effect of study arm on prostate cancer treatment in the large screening trial ERSPC. Int J Cancer. 2010;126:2387–2393. [PubMed: 19739124]
172.
van As NJ, Norman AR, Thomas K, et al. Predicting the probability of deferred radical treatment for localised prostate cancer managed by active surveillance. Eur Urol. 2008;54:1297–1305. [PubMed: 18342430]
173.
Mills N, Metcalfe C, Ronsmans C, et al. A comparison of socio-demographic and psychological factors between patients consenting to randomisation and those selecting treatment (the ProtecT study) Contemp Clin Trials. 2006;27:413–419. [PubMed: 16774847]
174.
el-Geneidy M, Garzotto M, Panagiotou I, et al. Delayed therapy with curative intent in a contemporary prostate cancer watchful-waiting cohort. BJU Int. 2004;93:510–515. [PubMed: 15008720]
175.
Wu H, Sun L, Moul JW, et al. Watchful waiting and factors predictive of secondary treatment of localized prostate cancer. J Urol. 2004;171:1111–1116. [PubMed: 14767282]
176.
Carter CA, Donahue T, Sun L, et al. Temporarily deferred therapy (watchful waiting) for men younger than 70 years and with low-risk localized prostate cancer in the prostate-specific antigen era. J Clin Oncol. 2003;21:4001–4008. [PubMed: 14581423]
177.
Yan Y, Carvalhal GF, Catalona WJ, et al. Primary treatment choices for men with clinically localized prostate carcinoma detected by screening. Cancer. 2000;88:1122–1130. [PubMed: 10699903]
178.
Sommers BD, Beard CJ, D’Amico AV, Kaplan I, Richie JP, Zeckhauser RJ. Predictors of patient preferences and treatment choices for localized prostate cancer. Cancer. 2008;113:2058–2067. [PubMed: 18704993]
179.
Meng MV, Elkin EP, Latini DM, et al. Treatment of patients with high risk localized prostate cancer: results from cancer of the prostate strategic urological research endeavor (CaPSURE) Journal of Urology. 2005;173:1557–1561. [PubMed: 15821485]
180.
Roberts CB, Albertsen PC, Shao YH, et al. Patterns and correlates of prostate cancer treatment in older men. Am J Med. 2011;124:235–243. [PubMed: 21396507]
181.
van den Bergh RC, Essink-Bot ML, Roobol MJ, et al. Anxiety and distress during active surveillance for early prostate cancer. Cancer. 2009;115:3868–3878. [PubMed: 19637245]
182.
Ramsey SD, Zeliadt SB, Fedorenko CR, et al. Patient preferences and urologist recommendations among local-stage prostate cancer patients who present for initial consultation and second opinions. World J Urol. 2011;29:3–9. [PubMed: 20959991]
183.
Davison BJ, Oliffe JL, Pickles T, et al. Factors influencing men undertaking active surveillance for the management of low-risk prostate cancer. Oncol Nurs Forum. 2009;36:89–96. [PubMed: 19136342]
184.
Durham J, Low M, McLeod D. Screening for prostate cancer: a survey of New Zealand general practitioners. N Z Med J. 2003;116:U476. [PubMed: 12835804]
185.
Diefenbach MA, Dorsey J, Uzzo RG, et al. Decision-making strategies for patients with localized prostate cancer. Semin Urol Oncol. 2002;20:55–62. [PubMed: 11828358]
186.
Zietman AL, Thakral H, Wilson L, et al. Conservative management of prostate cancer in the prostate specific antigen era: the incidence and time course of subsequent therapy. J Urol. 2001;166:1702–1706. [PubMed: 11586206]
187.
Holmboe ES, Concato J. Treatment decisions for localized prostate cancer: asking men what's important. J Gen Intern Med. 2000;15:694–701. [PMC free article: PMC1495597] [PubMed: 11089712]
188.
Fowler FJ Jr, McNaughton CM, Albertsen PC, et al. Comparison of recommendations by urologists and radiation oncologists for treatment of clinically localized prostate cancer. JAMA. 2000;283:3217–3222. [PubMed: 10866869]
189.
Chapple A, Ziebland S, Herxheimer A, et al. Is ‘watchful waiting’ a real choice for men with prostate cancer? A qualitative study. BJU Int. 2002;90:257–264. [PubMed: 12133062]
190.
Demark-Wahnefried W, Schildkraut JM, Iselin CE, et al. Treatment options, selection, and satisfaction among African American and white men with prostate carcinoma in North Carolina. Cancer. 1998;83:320–330. [PubMed: 9669815]
191.
Berry DL, Ellis WJ, Woods NF, et al. Treatment decision-making by men with localized prostate cancer: the influence of personal factors. Urol Oncol. 2003;21:93–100. [PubMed: 12856636]
192.
Steginga SK, Occhipinti S, Gardiner RA, et al. Making decisions about treatment for localized prostate cancer. BJU Int. 2002;89:255–260. [PubMed: 11856106]
193.
Crawford ED, Bennett CL, Stone NN, et al. Comparison of perspectives on prostate cancer: analyses of survey data. Urology. 1997;50:366–372. [PubMed: 9301699]
194.
O’Rourke ME. Narrowing the options: the process of deciding on prostate cancer treatment. Cancer Invest. 1999;17:349–359. [PubMed: 10370363]
195.
Anandadas CN, Clarke NW, Davidson SE, et al. Early prostate cancer--which treatment do men prefer and why? BJU International. 2011;107:1762–1768. [PubMed: 21083643]
196.
Xu J, Dailey RK, Eggly S, et al. Men’s perspectives on selecting their prostate cancer treatment. Journal of the National Medical Association. 2011;103:468–478. [PubMed: 21830629]
197.
Lin GA, Aaronson DS, Knight SJ, et al. Patient decision aids for prostate cancer treatment: a systematic review of the literature. CA Cancer J Clin. 2009;59:379–390. [PubMed: 19841280]
198.
Jang TL, Bekelman JE, Liu Y, et al. Physician visits prior to treatment for clinically localized prostate cancer. Arch Intern Med. 2010;170:440–450. [PMC free article: PMC4251764] [PubMed: 20212180]
199.
Shavers VL, Brown M, Klabunde CN, et al. Race/ethnicity and the intensity of medical monitoring under ‘watchful waiting’ for prostate cancer. Med Care. 2004;42:239–250. [PubMed: 15076823]
200.
D’Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280:969–974. [PubMed: 9749478]
201.
Shariat SF, Karakiewicz PI, Roehrborn CG, et al. An updated catalog of prostate cancer predictive tools. Cancer. 2008;113:3075–3099. [PubMed: 18823041]
202.
Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17:1–12. [PubMed: 8721797]
203.
Auvinen A, Hakama M, la-Opas M, et al. A randomized trial of choice of treatment in prostate cancer: the effect of intervention on the treatment chosen. BJU Int. 2004;93:52–56. [PubMed: 14678367]
204.
Davison BJ, Goldenberg SL, Wiens KP, et al. Comparing a generic and individualized information decision support intervention for men newly diagnosed with localized prostate cancer. Cancer Nurs. 2007;30:E7–15. [PubMed: 17876177]
205.
Davison BJ, Degner LF. Empowerment of men newly diagnosed with prostate cancer. Cancer Nurs. 1997;20:187–196. [PubMed: 9190093]
206.
Elwyn G, O’Connor A, Stacey D, et al. Developing a quality criteria framework for patient decision aids: online international Delphi consensus process. BMJ. 2006;333:417. [PMC free article: PMC1553508] [PubMed: 16908462]
207.
Hadley J, Yabroff KR, Barrett MJ, et al. Comparative effectiveness of prostate cancer treatments: evaluating statistical adjustments for confounding in observational data. J Natl Cancer Inst. 2010;102:1780–1793. [PMC free article: PMC2994860] [PubMed: 20944078]
208.
Wong YN, Mitra N, Hudes G, et al. Survival associated with treatment vs observation of localized prostate cancer in elderly men. JAMA. 2006;296:2683–2693. [PubMed: 17164454]
209.
Albertsen PC, Hanley JA, Penson DF, et al. 13-year outcomes following treatment for clinically localized prostate cancer in a population based cohort. J Urol. 2007;177:932–936. [PubMed: 17296379]
210.
Bill-Axelson A, Holmberg L, Ruutu M, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med. 2005;352:1977–1984. [PubMed: 15888698]
211.
Iversen P, Madsen PO, Corle DK. Radical prostatectomy versus expectant treatment for early carcinoma of the prostate. Twenty-three year follow-up of a prospective randomized study. Scand J Urol Nephrol Suppl. 1995;172:65–72. [PubMed: 8578259]
212.
Hegarty J, Beirne PV, Walsh E, et al. Radical prostatectomy versus watchful waiting for prostate cancer. Cochrane Database Syst Rev. 2010:CD006590. [PubMed: 21069689]
213.
Bill-Axelson A, Holmberg L, Ruutu M, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med. 2011;364:1708–1717. [PubMed: 21542742]
214.
Johansson E, Bill-Axelson A, Holmberg L, et al. Time, symptom burden, androgen deprivation, and self-assessed quality of life after radical prostatectomy or watchful waiting: the Randomized Scandinavian Prostate Cancer Group Study Number 4 (SPCG-4) clinical trial. Eur Urol. 2009;55:422–430. [PubMed: 18783877]
215.
Steineck G, Helgesen F, Adolfsson J, et al. Quality of life after radical prostatectomy or watchful waiting. N Engl J Med. 2002;347:790–796. [PubMed: 12226149]
216.
Fransson P, Damber JE, Tomic R, et al. Quality of life and symptoms in a randomized trial of radiotherapy versus deferred treatment of localized prostate carcinoma. Cancer. 2001;92:3111–3119. [PubMed: 11753990]
217.
Choo R, Long J, Gray R, et al. Prospective survey of sexual function among patients with clinically localized prostate cancer referred for definitive radiotherapy and the impact of radiotherapy on sexual function. Support Care Cancer. 2010;18:715–722. [PubMed: 19506916]
218.
Elliott SP, Meng MV, Elkin EP, et al. Incidence of urethral stricture after primary treatment for prostate cancer: data From CaPSURE. J Urol. 2007;178:529–534. [PubMed: 17570425]
219.
Zhou EH, Ellis RJ, Cherullo E, et al. Radiotherapy and survival in prostate cancer patients: a population-based study. Int J Radiat Oncol Biol Phys. 2009;73:15–23. [PMC free article: PMC2742208] [PubMed: 18538495]
220.
Abdel-Wahab M, Reis IM, Hamilton K. Second primary cancer after radiotherapy for prostate cancer--a seer analysis of brachytherapy versus external beam radiotherapy. Int J Radiat Oncol Biol Phys. 2008;72:58–68. [PubMed: 18374503]
221.
Tewari A, Divine G, Chang P, et al. Long-term survival in men with high grade prostate cancer: a comparison between conservative treatment, radiation therapy and radical prostatectomy—a propensity scoring approach. J Urol. 2007;177:911–915. [PubMed: 17296374]
222.
Smith DP, King MT, Egger S, et al. Quality of life three years after diagnosis of localised prostate cancer: population based cohort study. BMJ. 2009;339:b4817. [PMC free article: PMC2784818] [PubMed: 19945997]
223.
Stattin P, Holmberg E, Johansson JE, et al. Outcomes in localized prostate cancer: National Prostate Cancer Register of Sweden follow-up study. J Natl Cancer Inst. 2010;102:950–958. [PMC free article: PMC2897875] [PubMed: 20562373]
224.
Thong MS, Mols F, Kil PJ, et al. Prostate cancer survivors who would be eligible for active surveillance but were either treated with radiotherapy or managed expectantly: comparisons on long-term quality of life and symptom burden. BJU Int. 2010;105:652–658. [PubMed: 19747357]
225.
Fransson P, Damber JE, Widmark A. Health-related quality of life 10 years after external beam radiotherapy or watchful waiting in patients with localized prostate cancer. Scand J Urol Nephrol. 2009;43:119–126. [PubMed: 18985545]
226.
Schapira MM, Lawrence WF, Katz DA, et al. Effect of treatment on quality of life among men with clinically localized prostate cancer. Med Care. 2001;39:243–253. [PubMed: 11242319]
227.
Lubeck DP, Litwin MS, Henning JM, et al. Changes in health-related quality of life in the first year after treatment for prostate cancer: results from CaPSURE. Urology. 1999;53:180–186. [PubMed: 9886609]
228.
Bacon CG, Giovannucci E, Testa M, et al. The impact of cancer treatment on quality of life outcomes for patients with localized prostate cancer. J Urol. 2001;166:1804–1810. [PubMed: 11586228]
229.
Litwin MS, Lubeck DP, Spitalny GM, et al. Mental health in men treated for early stage prostate carcinoma: a posttreatment, longitudinal quality of life analysis from the Cancer of the Prostate Strategic Urologic Research Endeavor. Cancer. 2002;95:54–60. [PubMed: 12115317]
230.
Schymura MJ, Kahn AR, German RR, et al. Factors associated with initial treatment and survival for clinically localized prostate cancer: results from the CDC-NPCR Patterns of Care Study (PoC1) BMC Cancer. 2010;10:152. [PMC free article: PMC2876077] [PubMed: 20403178]
231.
Berge V, Thompson T, Blackman D. Additional surgical intervention after radical prostatectomy, radiation therapy, androgen-deprivation therapy, or watchful waiting. Eur Urol. 2007;52:1036–1043. [PubMed: 17178188]
232.
Rice KR, Colombo ML, Wingate J, et al. Low risk prostate cancer in men >/= 70 years old: To treat or not to treat. Urol Oncol. 2011 [PubMed: 21872499]
233.
Rothman KJ. No adjustments are needed for multiple comparisons. Epidemiology. 1990;1:43–46. [PubMed: 2081237]
234.
Greenland S, Robins JM. Empirical-Bayes adjustments for multiple comparisons are sometimes useful. Epidemiology. 1991;2:244–251. [PubMed: 1912039]
235.
Penson DF, Schonfeld WH, Flanders SC, et al. Relationship of first-year costs of treating localized prostate cancer to initial choice of therapy and stage at diagnosis: results from the CAPSURE database. Urology. 2001;57:499–503. [PubMed: 11248628]
236.
Wilson LS, Tesoro R, Elkin EP, et al. Cumulative cost pattern comparison of prostate cancer treatments. Cancer. 2007;109:518–527. [PubMed: 17186528]
237.
Andersson SO, Andren O, Lyth J, et al. Managing localized prostate cancer by radical prostatectomy or watchful waiting: Cost analysis of a randomized trial (SPCG- 4) Scand J Urol Nephrol. 2011;45:177–183. [PubMed: 21265595]
238.
Ollendorf DA, Hayes JH, McMahon PM, et al. Management options for low-risk prostate cancer. Insitute for Clinical and Economic Review; 2009. Ref Type: Report.
239.
Ollendorf DA, Hayes JH, McMahon PM, et al. Active surveillance & radical prostatectomy for the management of low-risk, clinically-localized prostate cancer. Institute for Clinical and Economic Review; Nov 11, 2009. Ref Type: Report.
240.
Hayes JH, Ollendorf DA, Pearson SD, et al. Active surveillance compared with initial treatment for men with low-risk prostate cancer: a decision analysis. JAMA. 2010;304:2373–2380. [PMC free article: PMC3055173] [PubMed: 21119084]
241.
Corcoran AT, Peele PB, Benoit RM. Cost comparison between watchful waiting with active surveillance and active treatment of clinically localized prostate cancer. Urology. 2010;76:703–707. [PubMed: 20381846]
242.
Eldefrawy A, Katkoori D, Abramowitz M, et al. Active surveillance vs. treatment for low-risk prostate cancer: A cost comparison. Urol Oncol. 2011 [PubMed: 21616691]
243.
Robins J, Orellana L, Rotnitzky A. Estimation and extrapolation of optimal treatment and testing strategies. Stat Med. 2008;27:4678–4721. [PubMed: 18646286]
244.
Hernan MA, Lanoy E, Costagliola D, et al. Comparison of dynamic treatment regimes via inverse probability weighting. Basic Clin Pharmacol Toxicol. 2006;98:237–242. [PubMed: 16611197]
245.
Srigley JR, Amin MB, Bostwick DG, et al. Updated protocol for the examination of specimens from patients with carcinomas of the prostate gland: a basis for checklists. Cancer Committee. Arch Pathol Lab Med. 2000;124:1034–1039. [PubMed: 10888780]
246.
Thompson IM, Canby-Hagino E, Lucia MS. Stage migration and grade inflation in prostate cancer: Will Rogers meets Garrison Keillor. J Natl Cancer Inst. 2005;97:1236–1237. [PubMed: 16145036]
247.
Epstein JI. Gleason score 2–4 adenocarcinoma of the prostate on needle biopsy: a diagnosis that should not be made. Am J Surg Pathol. 2000;24:477–478. [PubMed: 10757394]
248.
Giordano SH, Kuo YF, Duan Z, et al. Limits of observational data in determining outcomes from cancer therapy. Cancer. 2008;112:2456–2466. [PMC free article: PMC3856661] [PubMed: 18428196]
249.
Tseng KS, Landis P, Epstein JI, et al. Risk stratification of men choosing surveillance for low risk prostate cancer. J Urol. 2010;183:1779–1785. [PMC free article: PMC3474981] [PubMed: 20304433]